Annovis Bio remains a high-risk, pre-revenue biotechnology firm entirely dependent on external financing to advance its Buntanetap program. The company faces a critical liquidity inflection point as R&D expenditures surged to $16.7 billion in 2026Q1, significa...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.40+11.8% vs -$0.45 | — vs — |
Q2 2026 May 15, 2026 | -$0.63-59.5% vs -$0.40 | — vs — |
Q2 2026 Mar 16, 2026 | -$0.39-26.5% vs -$0.31 | — vs — |
Q4 2025 Nov 12, 2025 | -$0.37-2.8% vs -$0.36 | — vs — |
Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Annovis Bio NYSE: ANVS said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer's disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements.
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.
MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026.
Benchmark ANVS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Annovis Bio, Inc. (ANVS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.27 | $54.03M | -0.91 | — | — | -220.61% | — | |
| $0.94 | $45.26M | -1.80 | — | — | -95.77% | — | |
| $8.68 | $454.43M | -1.92 | -92.84% | -80.67% | -14.98% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $2.35 | $217.78M | -4.35 | — | — | -30.07% | — | |
| $4.34 | $17.12M | -0.18 | — | — | -411.58% | — |
Annovis Bio, Inc. (ANVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Annovis Bio, Inc. (ANVS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Jul 10, 2026·SEC
Jun 17, 2026·SEC
Get notified when ANVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Annovis Bio, Inc. (ANVS) stock FAQ — growth, dividends, profitability & financials explained
Annovis Bio, Inc. (ANVS) reported a net loss of $49.5M for fiscal year 2025.
Annovis Bio, Inc. (ANVS) has a return on equity (ROE) of -220.6%. Negative ROE indicates the company is unprofitable.
Annovis Bio, Inc. (ANVS) had negative free cash flow of $43.3M in fiscal year 2025, likely due to heavy capital investments.
